Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease

Fig. 4

Characterisation of dGAE aggregation inhibition properties of the anti-tau scAb panel - (A) Schematic representation of the thioflavin T assay showing increased fluorescence with the progression of aggregation. (B) Ranking the aggregation inhibition potency of lead core-region scAbs using the thioflavin T assay, where aggregation inhibition of dGAE was quantified by calculating the percentage change of peak fluorescence. One-way ANOVA with Dunnett’s test compared individual anti-tau scAbs to negative control (mean of six different negative control scAbs). (C) Schematic representation of tau-tau immunoassay (B50) used to rank anti-tau scAb aggregation inhibition (adapted from [51]). (D) An example of B50 assay, comparing NS2A1 with N-terminal -ve control 3aD6 scAb. n = 4 per scAb with six different -ve control scAbs (C- or N-terminal targeting) were used. (E) Table shows calculated B50 values for core scAbs.

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193